DEUTSCHOVÁ, Barbora and Ivan REKTOR. Deep brain stimulation of the anterior nuclei of the thalamus in focal epilepsy. Clinical Neurophysiology. Clare: Elsevier Ireland, 2022, vol. 144, December 2022, p. 1-7. ISSN 1388-2457. Available from: https://dx.doi.org/10.1016/j.clinph.2022.09.002.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Deep brain stimulation of the anterior nuclei of the thalamus in focal epilepsy
Authors DEUTSCHOVÁ, Barbora (203 Czech Republic, belonging to the institution) and Ivan REKTOR (203 Czech Republic, guarantor, belonging to the institution).
Edition Clinical Neurophysiology, Clare, Elsevier Ireland, 2022, 1388-2457.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30210 Clinical neurology
Country of publisher Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.700
RIV identification code RIV/00216224:14110/22:00129377
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.clinph.2022.09.002
UT WoS 000886064800001
Keywords in English Anterior thalamic nuclei; Focal epilepsy; Deep brain stimulation
Tags 14110127, podil, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 18/1/2023 12:36.
Abstract
Objective: To review the therapeutic effects of deep brain stimulation of the anterior nuclei of the thala-mus (ANT-DBS) and the predictors of its effectiveness, safety, and adverse effects. Methods: A comprehensive search of the medical literature (PubMed) was conducted to identify relevant articles investigating ANT-DBS therapy for epilepsy. Out of 332 references, 77 focused on focal epilepsies were reviewed. Results: The DBS effect is probably due to decreased synchronization of epileptic activity in the cortex. The potential mechanisms from cellular to brain network levels are presented. The ANT might participate actively in the network elaborating focal seizures. The effects of ANT-DBS differed in various studies; ANT-DBS was linked with a 41% seizure frequency reduction at 1 year, 69% at 5 years, and 75% at 7 years. The most frequently reported adverse effects, depression and memory impairment, were considered non -serious in the long-term follow-up view. ANT-DBS also has been used in a few cases to treat status epilep-ticus. Conclusions: We reviewed the clinical literature and identified several factors that may predict seizure outcome following DBS therapy. More large-scale trials are required since there is a need to explore stim-ulation settings, apply patient-tailored therapy, and identify the presurgical predictors of patient response. Significance: A critical review of the published literature on ANT-DBS in focal epilepsy is presented. ANT-DBS mechanisms are not fully understood; possible explanations are provided. Biomarkers of ANT-DBS effectiveness may lead to patient-tailored therapy.
Links
GA21-25953S, research and development projectName: Subkortikální jádra a kortikální funkce z perspektivy hluboké mozkové stimulace (Acronym: DBS3D)
Investor: Czech Science Foundation, Subcortical nuclei and cortical functions – insight from the deep brain stimulation perspective
PrintDisplayed: 18/7/2024 02:26